{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:08:34Z","timestamp":1790428114501,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":1528,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Onconova Therapeutics, Inc."},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1093\/annonc\/mdv264","type":"journal-article","created":{"date-parts":[[2015,6,19]],"date-time":"2015-06-19T22:16:39Z","timestamp":1434752199000},"page":"1923-1929","source":"Crossref","is-referenced-by-count":90,"title":["A phase II\/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer"],"prefix":"10.1016","volume":"26","author":[{"given":"B.H.","family":"O'Neil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.W.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.L.","family":"Aisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.","family":"Menter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Tejani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.K.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Granfortuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Coveler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.O.","family":"Olowokure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Baranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cusnir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Phillip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Boles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Nazemzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rarick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Radford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Fehrenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Bathini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Fanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"McRee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Maniar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jimeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.L.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.A.","family":"Messersmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdv264_bb0010","series-title":"Cancer Facts & Figures 2014","author":"Society","year":"2014"},{"issue":"9414","key":"10.1093\/annonc\/mdv264_bb0015","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(04)15841-8","article-title":"Pancreatic cancer","volume":"363","author":"Li","year":"2004","journal-title":"Lancet"},{"issue":"6","key":"10.1093\/annonc\/mdv264_bb0020","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1093\/annonc\/mdv264_bb0025","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1093\/annonc\/mdv264_bb0030","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv264_bb0035","first-page":"187","article-title":"Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer","volume":"7","author":"Al-Hajeili","year":"2014","journal-title":"OncoTargets Ther"},{"issue":"5","key":"10.1093\/annonc\/mdv264_bb0040","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1158\/1535-7163.641.3.5","article-title":"Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer","volume":"3","author":"Gray","year":"2004","journal-title":"Mol Cancer Ther"},{"issue":"34","key":"10.1093\/annonc\/mdv264_bb0045","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1200\/JCO.2008.17.9788","article-title":"Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors","volume":"26","author":"Jimeno","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdv264_bb0050","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-11-2813","article-title":"Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer","volume":"18","author":"Ma","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"Suppl 19","key":"10.1093\/annonc\/mdv264_bb0055","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/1538-7445.AM2014-LB-108","article-title":"Targeting the Ras-Binding domain of Ras effector proteins by a small molecule inhibitor, Rigosertib","volume":"74","author":"Divakar","year":"2014","journal-title":"Cancer Res"},{"issue":"17","key":"10.1093\/annonc\/mdv264_bb0060","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/sj.onc.1208617","article-title":"Getting in and out of mitosis with Polo-like kinase-1","volume":"24","author":"Van Vugt","year":"2005","journal-title":"Oncogene"},{"issue":"2","key":"10.1093\/annonc\/mdv264_bb0065","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/1535-7163.MCT-09-0693","article-title":"A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer","volume":"9","author":"Jimeno","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1093\/annonc\/mdv264_bb0070","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1517\/13543784.2011.562192","article-title":"New phosphatidylinositol 3-kinase inhibitors for cancer","volume":"20","author":"Bowles","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"issue":"5897","key":"10.1093\/annonc\/mdv264_bb0075","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1126\/science.1164368","article-title":"Core signaling pathways in human pancreatic cancers revealed by global genomic analyses","volume":"321","author":"Jones","year":"2008","journal-title":"Science (New York, N.Y.)"},{"issue":"5","key":"10.1093\/annonc\/mdv264_bb0080","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/bjc.2014.215","article-title":"Oncogenic KRAS signalling in pancreatic cancer","volume":"111","author":"Eser","year":"2014","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1093\/annonc\/mdv264_bb0085","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/onc.2008.424","article-title":"Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay","volume":"28","author":"Jimeno","year":"2009","journal-title":"Oncogene"},{"issue":"6","key":"10.1093\/annonc\/mdv264_bb0090","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccr.2009.03.022","article-title":"A gene expression signature associated with \u2018K-Ras addiction\u2019 reveals regulators of EMT and tumor cell survival","volume":"15","author":"Singh","year":"2009","journal-title":"Cancer cell"},{"issue":"4","key":"10.1093\/annonc\/mdv264_bb0095","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm.2344","article-title":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","volume":"17","author":"Collisson","year":"2011","journal-title":"Nat Med"},{"issue":"4","key":"10.1093\/annonc\/mdv264_bb0100","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/bjh.12436","article-title":"Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes","volume":"162","author":"Komrokji","year":"2013","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1093\/annonc\/mdv264_bb0105","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/hon.2137","article-title":"Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy","volume":"33","author":"Silverman","year":"2014","journal-title":"Hematol Oncol"},{"key":"10.1093\/annonc\/mdv264_bb0110","article-title":"A phase II study of the orally administered rigosertib (ON 01910.Na) in transfusion-dependent lower-risk myelodysplastic syndrome (MDS) patients","volume":"7031","author":"Raza","year":"2013","journal-title":"J Clin Oncol 31"},{"issue":"3","key":"10.1093\/annonc\/mdv264_bb0115","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/cas.12605","article-title":"Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2\/M arrest","volume":"106","author":"Hyoda","year":"2015","journal-title":"Cancer Sci"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341931765X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341931765X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/9\/1923\/16701250\/mdv264.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T12:58:30Z","timestamp":1691758710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341931765X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S092375341931765X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv264","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}